Amlodipine (Atorvastatin)

Generic Name

Atorvastatin

Brand Names

Amlodipine, Amlodipine Besylate, Atorvaliq, Azor, Benazepril, Benicar, Caduet, Katerzia, Lipitor, Lotensin, Lotrel, Norliqva, Norvasc, Olmesartan Medoxomil, Olmesartan Medoxomil Amlodipine, Sdamlo, Tribenzor

FDA approval date: June 21, 1991

Classification: Calcium Channel Blocker

Form: Tablet, Suspension, Capsule, Solution

What is Amlodipine (Atorvastatin)?

Amlodipine and benazepril hydrochloride capsules are a combination capsule of amlodipine, a dihydropyridine calcium channel blocker and benazepril, an angiotensin-converting enzyme inhibitor. Amlodipine and benazepril hydrochloride capsules are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent.

Approved To Treat

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

Phase II Interventional Study Using Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

Who is this study for: Individuals with head and neck cancer

Enrollment Status: Recruiting

Publish Date: September 02, 2026

Intervention Type: Other, Drug

Study Drug: Atorvastatin

Study Phase: Phase 2

Background: Cisplatin is used to treat head and neck cancer. People who take this drug are at risk for hearing loss. Atorvastatin is a drug used to treat high cholesterol. It might reduce the risk of cisplatin-induced hearing loss.

PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)

Who is this study for: Healthy adults over 75

Enrollment Status: Recruiting

Publish Date: September 01, 2026

Intervention Type: Drug

Study Drug: Atorvastatin

Study Phase: Phase 4

Summary: PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability a...

Clinical Study of CD123 Targeting Chimeric Antigen Receptor NK Cells (CAR-NK) in the Treatment of Relapse/Refractory Acute Myeloid Leukemia (AML)or Blastic Plasmacytoid Dendritic Cell Neoplasm(BPDCN)

Enrollment Status: Recruiting

Publish Date: August 28, 2026

Intervention Type: Drug

Study Phase: Phase 1

Summary: This is a clincal trial initiated by investigator to evaluate the safety and efficacy of anti-CD123 CAR-NK in the treatment of patients with relapsed/refractory acute myeloid leukemia or blastic plasma cell like dendritic cell tumors.

View All Clinical Trials